S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:NSTG

NanoString Technologies Competitors

$74.36
+4.57 (+6.55 %)
(As of 03/1/2021 05:20 PM ET)
Add
Compare
Today's Range
$70.39
Now: $74.36
$75.12
50-Day Range
$63.59
MA: $74.29
$82.96
52-Week Range
$13.85
Now: $74.36
$86.42
Volume809,747 shs
Average Volume643,868 shs
Market Capitalization$3.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77

Competitors

NanoString Technologies (NASDAQ:NSTG) Vs. RGEN, QGEN, NBIX, CRSP, DNLI, and XLRN

Should you be buying NSTG stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to NanoString Technologies, including Repligen (RGEN), QIAGEN (QGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), and Acceleron Pharma (XLRN).

Repligen (NASDAQ:RGEN) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Insider & Institutional Ownership

84.3% of Repligen shares are held by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are held by institutional investors. 1.7% of Repligen shares are held by company insiders. Comparatively, 4.2% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Repligen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Repligen and NanoString Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repligen00503.00
NanoString Technologies01402.80

Repligen currently has a consensus price target of $204.75, indicating a potential downside of 7.15%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than NanoString Technologies.

Profitability

This table compares Repligen and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repligen13.40%6.58%5.00%
NanoString Technologies-53.47%-68.96%-24.15%

Valuation & Earnings

This table compares Repligen and NanoString Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repligen$270.24 million44.86$21.41 million$1.07206.84
NanoString Technologies$125.57 million26.14$-40,700,000.00($1.93)-38.60

Repligen has higher revenue and earnings than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Summary

Repligen beats NanoString Technologies on 11 of the 14 factors compared between the two stocks.

QIAGEN (NYSE:QGEN) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Insider & Institutional Ownership

43.6% of QIAGEN shares are held by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are held by institutional investors. 9.0% of QIAGEN shares are held by company insiders. Comparatively, 4.2% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

QIAGEN has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for QIAGEN and NanoString Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN16902.50
NanoString Technologies01402.80

QIAGEN currently has a consensus price target of $56.3689, indicating a potential upside of 12.18%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given QIAGEN's higher possible upside, analysts clearly believe QIAGEN is more favorable than NanoString Technologies.

Profitability

This table compares QIAGEN and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
NanoString Technologies-53.47%-68.96%-24.15%

Valuation & Earnings

This table compares QIAGEN and NanoString Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion7.50$-41,460,000.00$1.4335.14
NanoString Technologies$125.57 million26.14$-40,700,000.00($1.93)-38.60

NanoString Technologies has lower revenue, but higher earnings than QIAGEN. NanoString Technologies is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Summary

QIAGEN beats NanoString Technologies on 9 of the 14 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Insider & Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 4.2% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Neurocrine Biosciences has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Neurocrine Biosciences and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
NanoString Technologies-53.47%-68.96%-24.15%

Valuation & Earnings

This table compares Neurocrine Biosciences and NanoString Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million13.05$37.01 million$0.39280.77
NanoString Technologies$125.57 million26.14$-40,700,000.00($1.93)-38.60

Neurocrine Biosciences has higher revenue and earnings than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Neurocrine Biosciences and NanoString Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences081102.58
NanoString Technologies01402.80

Neurocrine Biosciences currently has a consensus price target of $129.2222, indicating a potential upside of 18.40%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than NanoString Technologies.

Summary

Neurocrine Biosciences beats NanoString Technologies on 10 of the 14 factors compared between the two stocks.

CRISPR Therapeutics (NASDAQ:CRSP) and NanoString Technologies (NASDAQ:NSTG) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

66.4% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 17.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

CRISPR Therapeutics has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares CRISPR Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CRISPR Therapeutics-273.10%-20.72%-18.35%
NanoString Technologies-53.47%-68.96%-24.15%

Valuation and Earnings

This table compares CRISPR Therapeutics and NanoString Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$289.59 million33.73$66.86 million$1.17110.68
NanoString Technologies$125.57 million26.14$-40,700,000.00($1.93)-38.60

CRISPR Therapeutics has higher revenue and earnings than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for CRISPR Therapeutics and NanoString Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CRISPR Therapeutics241102.53
NanoString Technologies01402.80

CRISPR Therapeutics currently has a consensus price target of $150.20, indicating a potential upside of 13.90%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given CRISPR Therapeutics' higher possible upside, equities analysts plainly believe CRISPR Therapeutics is more favorable than NanoString Technologies.

Summary

CRISPR Therapeutics beats NanoString Technologies on 11 of the 14 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and NanoString Technologies (NASDAQ:NSTG) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

68.2% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 19.3% of Denali Therapeutics shares are owned by company insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Denali Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Denali Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Denali Therapeutics-968.59%-39.19%-30.71%
NanoString Technologies-53.47%-68.96%-24.15%

Valuation and Earnings

This table compares Denali Therapeutics and NanoString Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$26.68 million290.13$-197,610,000.00($2.07)-31.18
NanoString Technologies$125.57 million26.14$-40,700,000.00($1.93)-38.60

NanoString Technologies has higher revenue and earnings than Denali Therapeutics. NanoString Technologies is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Denali Therapeutics and NanoString Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Denali Therapeutics01902.90
NanoString Technologies01402.80

Denali Therapeutics currently has a consensus price target of $65.1111, indicating a potential downside of 1.32%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Denali Therapeutics is more favorable than NanoString Technologies.

Summary

Denali Therapeutics beats NanoString Technologies on 8 of the 14 factors compared between the two stocks.

Acceleron Pharma (NASDAQ:XLRN) and NanoString Technologies (NASDAQ:NSTG) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

79.8% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 2.5% of Acceleron Pharma shares are owned by company insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Acceleron Pharma has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Acceleron Pharma and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acceleron Pharma-157.84%-31.62%-28.11%
NanoString Technologies-53.47%-68.96%-24.15%

Valuation and Earnings

This table compares Acceleron Pharma and NanoString Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acceleron Pharma$73.99 million115.13$-124,860,000.00($2.38)-59.40
NanoString Technologies$125.57 million26.14$-40,700,000.00($1.93)-38.60

NanoString Technologies has higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Acceleron Pharma and NanoString Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acceleron Pharma111012.85
NanoString Technologies01402.80

Acceleron Pharma currently has a consensus price target of $139.6923, indicating a potential downside of 2.16%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Acceleron Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Acceleron Pharma is more favorable than NanoString Technologies.

Summary

NanoString Technologies beats Acceleron Pharma on 9 of the 15 factors compared between the two stocks.

pixel
Ad Market Traders Institute
A Powerful Day Trading Strategy that can produce $300 - $500 in just 15 Minutes
Reserve your free virtual seat to an exclusive trading session with legendary trader Tyson Clayton

NanoString Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Repligen logo
RGEN
Repligen
1.5$221.32+4.0%$11.63 billion$270.24 million269.90Earnings Announcement
Analyst Revision
QIAGEN logo
QGEN
QIAGEN
1.7$50.25+0.5%$11.39 billion$1.53 billion62.04
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.1$109.50+0.0%$10.29 billion$788.10 million117.74Analyst Revision
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.5$129.50+2.9%$9.48 billion$289.59 million-39.72Analyst Report
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.1$64.55+11.2%$8.61 billion$26.68 million-29.21Earnings Announcement
Analyst Report
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.4$141.38+3.7%$8.20 billion$73.99 million-54.59Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
Vir Biotechnology logo
VIR
Vir Biotechnology
0.8$66.47+5.8%$7.98 billion$8.09 million-28.17Earnings Announcement
Fate Therapeutics logo
FATE
Fate Therapeutics
1.6$96.56+7.1%$7.83 billion$10.68 million-52.48Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.2$57.68+1.9%$7.74 billion$85.07 million-60.72Earnings Announcement
Analyst Report
Twist Bioscience logo
TWST
Twist Bioscience
1.2$146.55+6.1%$6.70 billion$90.10 million-39.08
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.16+2.0%$6.12 billion$195.99 million288.50Earnings Announcement
Analyst Revision
Kodiak Sciences logo
KOD
Kodiak Sciences
1.3$135.98+5.1%$5.78 billionN/A-58.61Analyst Downgrade
News Coverage
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$39.59+5.8%$5.47 billionN/A-20.62Earnings Announcement
Analyst Revision
News Coverage
Beam Therapeutics logo
BEAM
Beam Therapeutics
0.9$95.69+6.9%$5.17 billion$20,000.00-6.81Analyst Downgrade
Analyst Revision
Gap Down
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$36.46+4.8%$4.87 billionN/A-17.12Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.23+1.1%$4.71 billion$503.70 million33.03Increase in Short Interest
News Coverage
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.4$86.23+0.2%$4.20 billionN/A-49.56Earnings Announcement
Analyst Report
Gap Down
RLAY
Relay Therapeutics
1.8$40.55+1.8%$3.71 billionN/A0.00Gap Down
NantKwest logo
NK
NantKwest
1.1$33.45+2.8%$3.54 billion$40,000.00-47.11Decrease in Short Interest
Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.3$45.90+0.5%$3.03 billion$50.04 million0.00Upcoming Earnings
Editas Medicine logo
EDIT
Editas Medicine
1.2$46.92+6.5%$2.75 billion$20.53 million-26.97Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Down
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$10.27+5.8%$2.71 billion$31.43 million-7.03Gap Down
AlloVir logo
ALVR
AlloVir
1.4$38.03+3.9%$2.38 billionN/A0.00Gap Down
Vericel logo
VCEL
Vericel
1.3$48.01+0.6%$2.19 billion$117.85 million-4,801,000.00Earnings Announcement
Analyst Downgrade
Analyst Revision
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.71+1.5%$2.13 billionN/A0.00Upcoming Earnings
News Coverage
bluebird bio logo
BLUE
bluebird bio
1.8$30.12+3.3%$2.06 billion$44.67 million-2.74Earnings Announcement
Analyst Revision
Ocugen logo
OCGN
Ocugen
1.1$10.00+9.5%$2.06 billionN/A-6.76Decrease in Short Interest
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.94+9.7%$1.90 billion$48.83 million-15.71Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$42.41+1.2%$1.85 billionN/A0.00Upcoming Earnings
Gap Down
Scholar Rock logo
SRRK
Scholar Rock
1.3$56.92+5.0%$1.82 billion$20.49 million-23.62Gap Down
Translate Bio logo
TBIO
Translate Bio
1.4$23.88+2.3%$1.73 billion$7.80 million-22.32Analyst Report
Gap Down
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.99+4.2%$1.63 billion$102.43 million-19.98Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.21+1.6%$1.61 billionN/A-19.89Gap Down
FMTX
Forma Therapeutics
1.8$38.21+1.0%$1.59 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
Krystal Biotech logo
KRYS
Krystal Biotech
1.3$85.00+7.2%$1.55 billionN/A-57.43Analyst Report
News Coverage
Gap Down
Immunovant logo
IMVT
Immunovant
1.8$14.86+6.2%$1.55 billionN/A-11.52Increase in Short Interest
Gap Down
REGENXBIO logo
RGNX
REGENXBIO
1.8$42.45+3.6%$1.53 billion$35.23 million-17.12Gap Down
Alector logo
ALEC
Alector
1.3$17.40+4.5%$1.44 billion$21.22 million-7.80Earnings Announcement
Gap Down
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$16.98+1.2%$1.30 billionN/A-3.68Gap Down
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$13.20+2.8%$1.25 billion$250,000.00-10.39Gap Down
PCVX
Vaxcyte
1.8$25.86+8.9%$1.20 billionN/A0.00Upcoming Earnings
Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$16.12+0.7%$1.17 billion$356.07 million7.90Earnings Announcement
Mesoblast logo
MESO
Mesoblast
1.4$9.60+0.7%$1.13 billion$32.16 million-10.91Upcoming Earnings
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.1$29.13+1.3%$1.10 billionN/A0.00Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$27.85+0.5%$1.01 billionN/A-4.60
Cortexyme logo
CRTX
Cortexyme
1.3$36.29+6.1%$1.00 billionN/A-15.12
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$26.50+3.4%$966.30 millionN/A0.00Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Gap Down
Inhibrx logo
INBX
Inhibrx
1.7$28.15+9.7%$958.64 millionN/A0.00Upcoming Earnings
Cellectis logo
CLLS
Cellectis
0.8$22.91+6.2%$913.45 million$22.99 million-12.19Upcoming Earnings
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$28.71+7.8%$884.35 millionN/A-11.86Gap Down
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.